Friday profile: The Molybdenum Man

Michael Druce, a life in nuclear medicine.

Michael Druce, a life in nuclear medicine.

Not everyone can claim that their work saves lives. But Michael Druce, who last week received the gong for Sustained Contribution at this year’s Australian Nuclear and Science Technology Organisation (ANSTO) research awards, is certainly among those who can.

For the last 37 years at ANSTO, Druce has focused on the manufacture and development of Molybdenum-99 (Mo-99) – a parent isotope of Technetium-99m, which is used in nuclear medicine to diagnose heart disease, skeletal injury and cancer.